Replies to post #2173 on Insmed Inc (INSM)

[Do DD]

Well, well, well,

TRCA & co have identified 60 potential patients in 17 Middle Eastern and North African countries for Primary IGFD.
Taiwan has about 23MM citizens. Given incidence for primary IGFD that would also tally to tens of patients max per year.
So let's be charitable and say that TRCA gets 100 patients per year from these countries. This leads to an extra income a 28000/year/patient of a staggering sum of $2.8MM.
This isn't sustainable. Nice PR stunt though. :-).

INSM should go for the Japanese and Chinese mainland market. 170 MM wealthy citizens (Japan) + 200MM (Chinese middleclass and up).

E.

[rod5247]

Found these sections of TRCA release at odds.

"December 2005, Tercica submitted a Marketing Authorization Application (MAA) for approval to market Increlex in the European Union (EU) for the same indication"

MAA submittted but not approved?

"We look forward to working with leading biopharmaceutical distributors in these regions where the FDA's approval of Increlex is expected to be recognized"

Expected to be recognized?

Lets put this PR in simple terms. We signed a distribution agreement and shipped Increlex because 60 potential patients have been identified in multiple countries and if the drug is approved and docs prescribe Increlex, some will be in Taiwan.

TRCA is a HooooooT!!!